AI-Designed Pan-TEAD Inhibitor ISM6331 to Show First Human Data at ESMO 2026
Insilico Medicine will present the first clinical data for its AI-designed pan-TEAD inhibitor ISM6331 in a Rapid Oral session at ...
Insilico Medicine will present the first clinical data for its AI-designed pan-TEAD inhibitor ISM6331 in a Rapid Oral session at ...
A new review in Molecular Cancer details how the TEAD family of transcription factors drives cancer, the drugs now targeting ...
A 40-year-old London patient with no occupational asbestos history was diagnosed with pleural mesothelioma, pointing researchers toward childhood environmental exposure ...
NIH researchers used CT contrast co-injection to map how directly injected drugs distribute in liver tissue, showing that small, multifocal ...
New research shows the immune checkpoint molecule VISTA also drives proliferation within mesothelioma cells through RIPK1-associated and AKT-dependent signalling, making ...
Researchers have distilled South Africa's state-funded asbestos rectification program into a governance framework showing that removing legacy asbestos from low-income ...
A groundbreaking study from the University of Vermont has revealed a novel approach to treating mesothelioma, a deadly cancer caused ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine